Blood stasis in congestive heart failure bears relation with digoxin clinical pharmacokinetics

Ai-Dong WEN,Xi HUANG,Yong-pei JIANG,Qi-Bing MEI,Lei ZHAO,Li ZHANG
DOI: https://doi.org/10.3321/j.issn:1000-2790.2001.07.015
2001-01-01
Abstract:AIM To study the influential factors in patients with congestive heart failure blood stasis on clinical pharmacokinetics of digoxin. METHODS Patients with congestive heart failure blood stasis were divided into two groups according to blood stasis degree and heart function. The first group (heart function Ⅰ~Ⅱ) included 34 cases with light blood stasis, while the second group (heart function Ⅲ~Ⅳ) included 38 cases with serious blood stasis. Patients of both groups were administered digoxin tables 0.125~0.385 mg*d-1 orally. Fluorescence Polarization Immunoassay (FPIA) was used to measure serum steady state digoxin concentrations, the method of one point of Bayesian to calculate digoxin clinical pharmacokinetics parameters, and the pharmacokinetics parameters of two groups were compared statistically. RESULTS With the aggravation of blood stasis and heart function damage, the Vd and CL of digoxin decreased markedly, but AUC of digoxin increased significantly. CONCLUSION The pharmacokinetics parameters are different in patients with different degrees of blood stasis in congestive heart failure, and the kidney function decrease is one of the major causes of this difference.
What problem does this paper attempt to address?